Miltefosine in children with visceral leishmaniasis

被引:0
作者
Singh, Utpal Kant
Prasad, Rajniti
Kumar, Ranjeet
Jaiswal, Bir Prasad
机构
[1] Nalanda Med Coll, Dept Pediat, Patna 800020, Bihar, India
[2] Banaras Hindu Univ, Inst Med Sci, Dept Pediat, Varanasi 221005, Uttar Pradesh, India
关键词
miltefosine; SAG (sodium antimony gluconate); visceral leishmaniasis (VL);
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Sixty four children (38 boys and 26 girls), aged 1 yr to 14 yr, presenting with fever, splenomegaly and positive LD body in splenic smear examination, admitted to pediatric ward of Nalanda Medical college and Child care center between 1st July 03 to 30th June 04 were taken for Study. Patients were categorized into two groups: 44 were in Group I (Patients who had not received prior anti-leishmanial drug) and 20 in Group II (Patients who had received 30 days course of SAG; 20 mg/kg/day). All patients were given Miltefosine in dose of 2.5 mg/kg/day od or bid per orally to a maximum of 100 mg and were followed at completion of therapy, 1 month and 6 months for clinical response, splenic size and parasite density. 63 patients had parasitological cure with relapse in one patient of Group I during follow up. One patient in Group II had no response with first course but became parasitologically negative with 2nd course of Miltefosine. In Group 1, one patient had persistent splenomegaly and found to have associated portal hypertension. GI side effects i.e. diarrhea and vomiting were observed in 26 and 23 patients respectively. Majority of patients had pancytopenia. Elevated ALT (>3 times of normal) were seen in 28 and 11 patients of Group I and Group II respectively which returned to normal in subsequent follow up. The final cure rates were 93.2% and 95% in Groups I and II respectively.
引用
收藏
页码:1076 / 1080
页数:5
相关论文
共 50 条
  • [21] Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis
    Sane, Shraddha A.
    Shakya, Nishi
    Gupta, Suman
    [J]. EXPERIMENTAL PARASITOLOGY, 2011, 127 (02) : 376 - 381
  • [22] Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
    Fabio dos Santos Nogueira
    Valdir Carlos Avino
    Fredy Galvis-Ovallos
    Vera Lucia Pereira-Chioccola
    Marcio Antonio Batistella Moreira
    Ana Paula Peres Lopes Romariz
    Leticia M. Molla
    Ingrid Menz
    [J]. Parasites & Vectors, 12
  • [23] Miltefosine to treat leishmaniasis
    Berman, J
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1381 - 1388
  • [24] Miltefosine and cutaneous leishmaniasis
    Machado, Paulo R. L.
    Penna, Gerson
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (02) : 141 - 144
  • [25] MILTEFOSINE IN CUTANEOUS LEISHMANIASIS
    Rahman, Simeen Ber
    ul Bari, Arlan
    Mumtaz, Nadeem
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2007, 17 (03): : 132 - 135
  • [26] What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
    Sundar, Shyam
    Singh, Anup
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2013, 11 (02) : 117 - 119
  • [27] Miltefosine for Visceral and Cutaneous Leishmaniasis: Drug Characteristics and Evidence-Based Treatment Recommendations
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    [J]. CLINICAL INFECTIOUS DISEASES, 2015, 60 (09) : 1398 - 1404
  • [28] Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation
    Das, Samir
    Khan, Wahid
    Mohsin, Shaikh
    Kumar, Neeraj
    [J]. POLYMERS FOR ADVANCED TECHNOLOGIES, 2011, 22 (01) : 172 - 179
  • [29] Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis
    Gupta, S
    Ramesh
    Sharma, SC
    Srivastava, VML
    [J]. ACTA TROPICA, 2005, 94 (01) : 41 - 47
  • [30] Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis
    Fernandez-Garcia, Raquel
    Walsh, David
    O'Connell, Peter
    Passero, Luiz Felipe D.
    de Jesus, JessicaA.
    Laurenti, Marcia Dalastra
    Dea-Ayuela, Maria Auxiliadora
    Ballesteros, M. Paloma
    Lalatsa, Aikaterini
    Bolas-Fernandez, Francisco
    Healy, Anne Marie
    Serrano, Dolores R.
    [J]. MOLECULAR PHARMACEUTICS, 2025, 22 (03) : 1437 - 1448